“MHRA’s acceptance of the CTA to evaluate ST101 in patients with advanced cancer indications allows the start of our first clinical development program,” said Barry Kappel, Ph.D., M.B.A., founder and Chief Executive Officer of Sapience Therapeutics. “We want to immediately start the ST101 trial to evaluate the first targeted therapeutic peptide that is able to interfere with the interaction of specific intracellular proteins that occur in cancer cells. This ability to achieve ‘unbeatable targets’ has the potential to change outcomes for patients who critically need new treatment options. “

ST101 is a peptide antagonist of C / EBPβ transcription factors, which are usually expressed and active in stem cells or early progenitor cells but not in most mature or differentiated cells. Certain cancers activate C / EBPβ, which produces gene expression with a role in cell proliferation, differentiation, and cell cycles. Disruption of this transcription factor with ST101 results in the target of killing cancer cells, because normal cells do not depend on C / EBPβ-driven transcription to survive.

Phase 1/2 studies will be conducted on patients who are not eligible for other therapies or have progressed on previous therapies. In addition to evaluating safety and tolerability, this study will assess the initial efficacy of ST101 in patients with four specific types of solid tumors, including glioblastoma, advanced / metastatic breast cancer, castration-resistant prostate cancer, and melanoma. Sapience hopes to open research at several clinical sites later this year.

www.sapiencetherapeutics.com. “data-reactid =” 17 “> Sapience Therapeutics, Inc., is a private preclinical biotechnology company that focuses on the discovery and development of peptide-based therapies for major medical needs that are not met, especially high cancer mortality. With the discovery of a peptide therapy-based platform that interfering with protein-protein interactions, Sapience molecules have the potential to target intracellular interactions that have traditionally been considered “targets that cannot be resisted.” Its main compound, ST101, is a first-class molecule with potential application in a variety of solid tumors and hematological malignancies. in 2016, Sapience Therapeutics closed its Series A financing, led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital.For more information about Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

This press release contains forward-looking statements, and any statement other than historical fact statements can be considered forward-looking statements. These forward-looking statements can include, inter alia, statements about future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events can differ materially as a result of certain factors, including, without limitation, the risks associated with applying net proceeds from bidding to the purpose of Sapience product development. , our ability to obtain additional funds, and meet applicable regulatory standards and receive regulatory approvals as needed. This is a forward-looking statement, which speaks only on the date of this press release. Sapience does not undertake any obligation to update forward-looking statements as a result of new information, future events, changes in assumptions or vice versa.

[email protected]“data-reactid =” 21 “> Sapience Therapeutics, Inc .:
Barry Kappel, Ph.D., M.B.A.
President and Chief Executive Officer
[email protected]

https://www.accesswire.com/588782/Sapience-Therapeutics-Receives-United-Kingdom-Authorization-to-Initiate-a-Phase-12-Trial-of-Lead-Candid-ST101-in-Advanced-Cancer- Indication

image source

to request modification Contact us at Here or [email protected]